Several pre-clinical and clinical trials show that exogenous pulmonary surfactant has clinical
efficacy in inflammatory lung diseases, especially ARDS. By infecting type II alveolar cells …

Abstract The coronavirus disease 2019 (COVID-19) rapidly spread across the globe,
infecting millions and causing hundreds of deaths. It has been now around three years but …

The pathogenetic mechanism of post-Covid-19 pulmonary fibrosis is currently a topic of
intense research interest, but still largely unexplored. The aim of this work was to carry out a …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus
disease 2019 (COVID-19), has become in the spotlight regarding the serious early and late …

How acute respiratory distress syndrome progresses from underlying disease or trauma is
poorly understood, and there are no generally accepted treatments resulting in a 40 …

SARS-CoV-2 directly targets alveolar epithelial cells and can lead to surfactant deficiency.
Early reports suggested surfactant replacement may be effective in improving outcomes. The …

Membrane recognition by viral spike proteins is critical for infection. Here we show the host
cell membrane-binding surfaces of severe acute respiratory syndrome coronavirus 2 (SARS …

Pulmonary surfactant has been attempted as a supportive therapy to treat COVID-19.
Although it is mechanistically accepted that the fusion peptide in the S2 subunit of the S …

Rationale: Coronavirus disease 2019 (COVID-19) can lead to acute respiratory distress
syndrome with fatal outcomes. Evidence suggests that dysregulated immune responses …

Background We have investigated the use of nebulized surfactant as a potential therapeutic
option for the patients with coronavirus disease 2019 (COVID-19)-associated acute …